Overview of Prostat
Quick Facts
| Property | Description |
|---|---|
| Active ingredient | Finasteride |
| Form | Film-coated tablet (Oral preparation) |
| Pharmacological class | 5alpha-Reductase inhibitor |
| General purpose | Mitigation of androgen-related effects |
| Origin | Synthetic compound (4-Azasteroid) |
Defining Prostat: The 5alpha-Reductase Inhibitor Class
Prostat is a prescription-only medicine whose identity is fundamentally derived from its active ingredient, Finasteride. This substance is identified as a synthetic compound chemically classified as a 4-Azasteroid. The drug formally belongs to the 5alpha-Reductase inhibitor pharmacological class. This class of medication is designed to modulate the body’s hormonal environment by blocking a specific enzymatic conversion. This classification signifies that the drug is designed to block the action of a natural enzyme, distinguishing it from conventional hormonal agents, and is typically employed in the therapeutic domain of male hormone-dependent conditions.
Composition and Form: The Oral Tablet Preparation
Prostat is provided as an oral preparation, supplied specifically as a film-coated tablet intended for systemic absorption via the oral route of administration. The preparation is defined as a single-ingredient product, containing only the active ingredient Finasteride alongside the necessary solid pharmaceutical excipients required to create the tablet matrix. This standardized, fixed-dose oral form is utilized for facilitating consistent absorption and systemic distribution of the medication to achieve therapeutic action within the body's target tissues. Unlike topical treatments, the oral tablet formulation is used for delivering the active substance for a systemic effect on hormonal processes.
The General Purpose of Prostat: Targeting Androgen Activity
The general therapeutic purpose of Prostat is to mitigate specific physiological changes driven by certain potent steroid hormones. The core mechanism of the drug centers on the enzyme inhibition of Type II 5alpha-reductase, a process that interferes with the conversion of testosterone into the more active derivative, dihydrotestosterone (DHT). This mechanism is intended to reduce the levels of this specific potent hormone. By reducing systemic and local levels of DHT, the medication aims to modulate the hormonal influence responsible for undesirable cell proliferation in androgen-related disorder therapy, thereby addressing the underlying cause of structural or functional changes in hormone-sensitive areas.
Regulatory References

